PRPO Stock Summary and Trading Ideas (Precipio | NASDAQ:PRPO)

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Precipio trades on the NASDAQ stock market under the symbol PRPO.

As of March 27, 2026, PRPO stock price declined to $25.97 with 22,335 million shares trading.

PRPO has a beta of 1.11, meaning it tends to be more sensitive to market movements. PRPO has a correlation of 0.06 to the broad based SPY ETF.

PRPO has a market cap of $45.50 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PRPO traded as high as $29.53 and as low as $3.90.

The top ETF exchange traded funds that PRPO belongs to (by Net Assets): VXF, VTI, DFSU, DCOR.

PRPO has outperformed the market in the last year with a price return of +314.8% while the SPY ETF gained +13.1%. PRPO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.3% and -3.3%, respectively, while the SPY returned -7.9% and -4.0%, respectively.

PRPO support price is $25.12 and resistance is $27.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRPO shares will trade within this expected range on the day.